Astrazeneca Ab

Merck Sharp + Dohme Corp.

Neurosearch A/s

Astra Zeneca U.k. Limited

Pharmacopeia Inc.

N.v. Organon

Merck Sharp + Dohme B.v.

Andrew Cooke

David R Cheshire

Martin E Cooper

Mark Furber

Matthew Wd Perry

David K Donald

Philip Vellacott Thorne

Koc-Kan Ho

Lene Teuber

Michael H Ohlmeyer

Nasrin Ansari

Yusheng Xiong

Bheemashankar A Kulkarni

Clare London

Min K Park

Scott B Hoyt

David Jonathan Bennett

Michelle Lee Morris

Emma Louise Carswell

Paul David Ratcliffe

Naheed Mirza

Jiaqiang Cai

Andrew Roughton

Irina Neagu

D Jonathan Bennett

Yajing Rong

Susan Elizabeth Napier

Frank Wätjen

Jui-Hsiang Chan

Niall Morton Hamilton

Rohit Saxena

Andrew Stanley Edwards

John MacLean

Archana Gupta

Morag Ann MacCall Easson

The invention involves compounds of structural Formula (I) and the pharmaceutically acceptable salts thereof. The compounds of the invention are effective at selectively inhibiting CYP11B2, and are therefore useful for the treatment or prophylaxis of disorders that are associated with elevated aldosterone levels, including, but not limited to, hypertension and heart failure. 

Aldosterone synthase inhibitors

The present invention relates to 1-(4-ureidobenzoyl)piperazine derivatives having the general Formula I (We bring to your attention that formula I is not provided on this electronic version as it is provided in the abstract of the paper copy) Wherein Ris (C)alkyl, (C)cycloalkyl or (C)cycloalkyl(C)alkyl, each of which may be substituted by hydroxy, cyano or halogen; Rrepresents 1 or 2 optional halogens; Ris (C)alkyl, (C)cycloalkyl or (C)cycloalkyl(C)alkyl, each of which may be substituted by one or more halogens; A represents a heteroaryl ring system comprising 1-3 heteroatoms selected from N, O and S, which ring system is 5- or 6-membered when X is C, and 5-membered when X is N; n is 1 or 2; or a pharmaceutically acceptable salt thereof; to pharmaceutical compositions comprising the same, and to the use of a these 1-(4-ureidobenzoyl)piperazine derivatives for the manufacture of a medicament for treating or preventing atherosclerosis and related disorders associated with cholesterol and bile acids transport and metabolism. 

1-(4-ureidobenzoyl)piperazine derivatives

This invention relates to novel 1,5,7-trisubstituted benzimidazole derivatives, pharmaceutical compositions containing these compounds, and methods of treatment therewith. The compounds of the invention are useful in the treatment of central nervous system diseases and disorders, which are responsive to modulation of the GABAreceptor complex.

[object Object]

The invention provides pharmaceutically useful thieno[2,3-d]pyrimidinediones, processes for their production, pharmaceutical compositions containing them and methods of treatment involving their use.

Treatment of skin disorders using thieno[2,3-D]pyrimidinediones

The invention provides pharmaceutically useful thieno&lsqb;2,3-d&rsqb;pyrimidinediones, processes for their production, pharmaceutical compositions containing them and methods of treatment involving their use.

Thieno&lsqb;2,3-d&rsqb; pyrimidinediones, their preparation and use in therapy

Thieno&lsqb;2,3-d&rsqb;pyrimidine diones and their use in the treatment of reversible obstructive airways diseases

Compounds

Growing community of inventors

East Kilbride, United Kingdom

Andrew Cooke